Merck Sharp + Dohme Corp.

Acumen Pharmaceuticals, Inc.

Weirong Wang

Paul J Shughrue

Alexander McCampbell

Wei-Qin Zhao

Fubao Wang

Renee C Gaspar

Ningyan Zhang

William F Goure

Min Xu

Yan Li

Peter Peizhi Luo

Pingyu Zhong

Andrei Alexandrovich Golosov

Feng Dong

Rose M Cubbon

Laurence B Peterson

Xinwei Wang

Mark Hsieh

Yan Ni

Abigail L Wolfe

Mary J Savage

Alexander Mccampbell

Kevin Caili Wang

Jon H Condra

Nigyan Zhang

Franz F Hefti

Noel Byrne

Stephen Soisson

Gopalakrishnan Parthasarathy

Jun Lu

Sujata Sharma

Kevin Caili Wangr

This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

The present invention relates to antibodies that bind amyloid &#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

Anti-ADDL monoclonal antibody and uses thereof

This invention is a selective A&#x3b2; oligomer kit and immunoassay method capable of reliably and sensitively detecting A&#x3b2; oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A&#x3b2; oligomer antibodies, as capture and detection antibodies, to detect and quantify A&#x3b2; oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

Antibodies, kit and method for detecting amyloid beta oligomers

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

AX132 PCSK9 antagonists

AX1 PCSK9 antagonists

Growing community of inventors

Harleysville, PA, United States of America

Weirong Wang